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Introduction
Tremendous advances are hein made in the treatment of gy neco—
locic cancers today Some of these ad ances are being made right
here In Hawaii. Gvnecologic cancer, including ovarian, fallopian
tube, primary peritoneal, cervical, vaginal, vulvar. endometrial.
uterine sarcoma. and gestational trophoblastic disease strike more
than 100,000 women a year in the United States resulting in tens ot
thousands of potentially preventable deaths. Exciting advances are
occurring in cancer surgery. chemotherap. radiotherap. and the
biological understanding of these cancers. This paper will review
the basics of the major cancers: o arian. cervical, and endometnal
and touch on some exciting nev ad\ ances.
Ovarian Cancer
Oxarian carcinoma is the second most common gy necologie malig
nancy in the United States. Each year, ovarian cancer strikes 26,000
women killing an estimated 14.000, This represents 55% of all
deaths from gvnecologic cancers, making ovarian cancer the most
lethal gvnecologic malignanc.
Epithelial ovarian tumorS. originate li’om coelomic epithelial cells
that cover the os arv and account for approximately 5% of all
ovarian cancers. Germ cell cancers and strornal cell cancers account
for the remaining proportion ol’ o an an cancer. Epi thel ial to inors
may he benign. “borderline” çlo\\ malignant potentiab. or inalig—
nant. The invasive epithelial cancers have a peak age incidence
between 55 and 65, although patients can he diagnosed from 10 to
100.
\Vhen considering ovarian cancer. most people refer to the most
common and most deadly type: epnhelial. T o other epithel al
O\ anan—lmke cancers arc fallopian tube and primary perttoneal.
hmch do not originate in the os ary , but are biologically virtually
ide iii i cal.
Ovarian cancer freguenil in’ ols e’ the unlentum andior retro—
permtoncal lmph nodes \\ith pleural effusions or parenchymal liver
metastasis, Approximately 70 of women present with advanced
Stage 111 and TV disease and have a median survis al rate of less than
25%. The overall survival for all epithelial ovarian cancer is 50%,
The survival rate for local, regional. and distant stage disease is
similarhetween Os arian carcinoma and breast carcinoma, However.
the os erall stirs sal (or women ss ith os arian cancer is substantially
less than for those women with breast cancer due in the preponder
ance of late stage ovarian cancers. Unlike mammography in breast
cancer, there is no effective screening test f’or ovarian cancer.
Combine this with f’ew specific early smptoms. and it is under
standable ss hv most v omen ss ith ovarian cancer are diagnosed v ith
Statze III and IV disease.
Only a less factors has e been linked to an increased risk or the
development of ovarian cancer. These include increasing age.
family history of breast or us arian cancer. personal history of colon
or breast cancer, and nulliparitv. Really. ss e don’t know what causes
this disease. On the otherhand. the risk of developing ovarian cancer
is reduced by 60% with fis e years of oral contraceptive use, The
protective effect of oral contraceptive use appears to he long-term.
In addition, pregnancy also reduces ovarian cancer risk, as does
tubal ligation and breast—feeding.
For ss omen in the eeneral population without a family history of
os arian cancer, the lifetime risk is about I in 60 or 1.6%. If a woman
has one first—degree relatis e (mother or Sister> with ovarian cancer.
that risk increases to I in 20 or 5%. It there are two brst—degree
relatives ss ith ovarian cancer. that risk increases to I in 14 or 7%.
Add in early age and that risk is even higher. Women who are
members of a family with a hereditary ovarian cancer syndrome
have a lifetime risk of’ developing ovarian cancer as high as 40%.
Women with a known BRCAI or BRCA2 germ line mutation have
a 35% to 65% risk of developing ovarian cancer in theirlifetime and
an even higher risk of developing breast cancer.
Hereditary us arian cancer accounts for 10% ofepithelial ovarian
carcinomas. In addition to the BRC.\ 1 and BRCA2 gene-related
breast/os arian cancer syndromes. HNPCC I Hereditary Non-Poly—
posis Colorectal Cancer> is another important cancer y ndrome
worthy of mention. This hei’editary syndrome, caused by a mutation
in the mismatch repair genes. increases the risk of not only’ colon
cancer, but also endometrial and ovarian cancer,
One strategy to reduce the risk of dying from ovarian cancer is the
use of oral contraceptive pi11s for ehemoprevention. Recent data
suggests that the progestational component of the pill may increase
us arian epithelial apoptosis. resulting in a lowered risk. Another
strategy is prophylactic oophorectomv. which dramatically reduces
the risk of des elopine ovarian cancer. However, even svith ouphorec—
tomv. lrmn1iry perituneal ‘‘m-nc can occur in 3% ol’ eases.
Unfortunately, there is no screening strategy available currently
that is sensitive and specific enough to offer to the general popula
tion. In high-risk populations, CA— 125 and transvaginal ultrasonog—
raphy may detect cancers earlier, hut this is unproven.
CA-I 25 is a serum tumor markerthat is des ated in 70% ofs’ omen
with advanced epithelial Os arman carcinoma. CA— 125 is an antibody
to the OC— 125 antinen found on many mesothelial surfaces. Al—
thoueh des amed in advanced disease. CA- 125 has not been shoss n to
be an effectis e screenmnc tool because it is elevated ni only 25% to
50 of Stage I cancers. Furthermore, because CA— 125 is des ated in
sO many other ni inmal mgnant conditions like endomnetrmosm s pelvic
inflammatory disease, pi’egnancv. liver and renal disease, it is not
reliable even if it is elevated. For this reason. CA-I 25 should not he
used as a screening test in the general population.
Ultrasottnd also has been advocated as a screening test for ovarian
cancer. Unfortunately, both tiansabdominal and transvaginal ultra
sound base a high false-positms e rates. In one study’. 5.00>> ss omen
were screened ss mth ultrasound. Smxty-fms e laparotomies 55 em’e needs-
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sarv in order to detect one case of earl ovarian cancer. In a
subsequent stud\ of I .200 women who had a strong famil history
of o’ arian cancer and ss ho underwent transvaeinal ultrasound
screening, there were 12 exploratory surgeries for ever case of
ovarian cancer. Current research aims at deselopino a more precise
ahil its to distinguish benign tumors from those that are malignant by
combining a variety 01 screening modalities.
er screening methods are currentl being ins estigated. Se
rum lvsophosphatidic acid (LPA) and a novel protein marker panel
are two blood marker detection methods that arc currently in early
trials hut appear very promising. Because early os arian cancer is
highly curable, it is worthwhile to continue searching for a better
screening method. We are currently formulating an ovarian cancer
screening trial here in Hawaii.
Contrar to what is commonl accepted. women ss ith ovarian
carcinoma do have s mptoms. In a recent study of os er 1.70(1
women ss ith all staces of epithelial ovarian cancer, over 90
reported that the\ had symptoms for a duration of I I 2 months prior
to their diagnosis. The problem with ovarian cancer symptoms is
that they are vague and generally not gvnecologmc. The most
common s mptoms reported are abdominal bloating with increased
abdominal girth, fatigue. and gastrointestinal disturbances, espe
cially constipation, diarrhea, early satiety. urinar symptoms, ab
dominal and pelvic pain, and menstrual irregularities.
Patients who present with abdominal, GI, GU, or gynecologic
complaints deserve a pelvic exam as part of a complete physical
evaluation. Making the diagnosis of ovarian cancercan be challeng
ing because the vague signs and symptoms, hut an early diagnosis
can riprove a chance at a cure. Ultrasounds and CT scans are the
best studies to mdentifva mass or ascites: hoss e’ er. the are currently
unable todefinmtmvelv distinguish benign from malignant neoplasms.
A CA— 125. when elevated, would indicate a higher likelihood that
an ovarian tumor is malignant. especially in a post—menopausal
woman, It is not appropriate to aspirate a mass or open a mass in the
abdominal cas itv because of the danger ot’ seeding the abdomen
with cloungenic cancer cells. In general, an patient with a suspi
cious ovarian mass or unexplained ascites with or without an
elevated CA- 125 should be rel’erred to a gynecologic oncologist for
specialty care.
Appropriate surgical staging in ovarian cancer is essential to
determine the appropriate choice of adjuvant theraps. One-third of
patients s ith presumed Stage I disease will he found to actually have
Stage III disease when the appropriate staging operation is per
h rmed . iii ads anced disease. uiaxi mal sureical c toreduct ion traits—
lates i [[to improved survival. Our recentl published data demon
strates that improved sursi’. al s as seen in ovarian cancer patients
who had a cynecologic oncologist ins olved in their care. This
impros ed surs sal i’ most likel due to the es necoh gie oncoloeists
tamiliarit\ with the disease and his or her extensive surgical training
directed at being able to remos e as much cancer as possible.
Unfartunately. the majorit\ of women who present with ovarian
cancer will have extensive pels ic and intra-ahdoniinal disease. For
these women, removal of all gross disease is considered optimal and
is associated with a significant survival advantage. Median survival
and cure rates following opti rnal cytoreduction are almost double
that of svomnen in whom the surgeons could not remos e all gross
disease and achieve an optimal result, Cytoreduction for ads anced
disease often requim’es i’emoval of large pelvic tumors with en bloc
resection of the uterus, ovaries, and recto sigmoid: resection of large
omental tumor cakes: small bowel resection’, and removal of exten
sive diaphragmatic and peritoneal implants. Significant surgical
expertise and special training are required to perform radical ovarian
cancer estoreductis e procedures.
Most patients svith os arian cancer requn’e adjuvant c hentotherap
after uimtial surgery. Results from cooperative group trials i.e..
G\ necologic Oncolog Group. Southwest Oncology’ Group) has e
found that the best initial chemotherapy for ovarian cancer is
Carhoplatin plus Taxol. We have now opened the GOG here in
Hasvaii. allowing our patients the opportunit\’ to be enrolled in trials
ollering new medications and novel combiriauons of existing che
motherapies with the hopes of improving survival.
GOG 182 offers triplet therapy and sequential double therap
ss ith Platinum. Taxol. Gemcitabine. Topetecan and Doxil as upfront
therapy . Another trial we have brought to Hawaii adds gamma—
interferon to upiront thcm’apv. Although most patients svith advanced
initial disease will achieve a complete clinical response after surger
and chemotherapy, patients ss ith advanced (Stage Ill and I \
Os arian cancer have a ver’% high recurrence rate approaching 8(Y
Treatment options for recurrent disease include a secondary
cytoreductive surgery. retreatment svith platinum and Taxol whei’e
retreatment responses can be as high as 50%. or multiple second-line
therapies including Topetecan, Doxil, Etoposide, Gemcitabine.
Hexalen. Ifosomide, Vinorelbine, Tamoxifen, or Herceptin. Partici
pation in clinical trials evaluating second—line agents is now avail
able here in Hawaii.
Cervical Cancer
Approximately 13.000 women in the United States develop cervical
caneereach year. resulting in 5.000deaths. Cervix cancer is the most
common and deadl cancer for svomen world ss ide. Fortunatel\
though. as a result of wide—spread earner screening svith the pap
smear. cervix cancer deaths in the United States are a fraction ot
svhat they were just 50 ears ago.
The risk factors for cervical cancer are well known. Most of them
are associated with risk factors forcontracti ng a sexually transmitted
disease. Women who begin intercourse at an early age are at a higher
risk. Those who have had multiple sexual partners or have a partner
vs ho themselves have had several partners place themselves at
higher risk
. Smokme is also a strong a risk factor as is lower
socioeconomic status and a histoi’ other of sexually transmitted
diseases.
Cervical cancer is a sexual1 transmitted disease and the human
papil lonia sii’us HPV s the causatis e agent. While up to 5tY of the
t nited States population is infected with l—lPV. onI a small mmnorit\
es er develop cervical lesions. This is because unI\ a handful of high-
risk t pe’ lead to cancer. Fhe great majorit of ss omen infected vs mth
HPV ss ill never des elop cancer.
The pap smear is a screening test for cers ical cancer that detects
abnormalities in the cers ical cells caused by l-IPV infection. A
woman should have her first Pap test and pelvic exam at the age of
18 or after the first onset of intercourse. whichever comes first, If a
woman is in a low—risk category after three consecutive. normal
annual examinations, the Pap test may he perfarmed somewhat less
Irequentls. Hosvever. if either the woman or her male partner is in
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a high-risk category, the Pap test should he continued to be per
formed on an annual basis for a lifetime. In today societ\ most
women are considered to be at risk.
The Pap smear is not acompletely accurate test. For an\ single Pap
smear, the false—negative rate is 2Of;. Fortunately, the latency period
a precancerous lesion to develop into invasive cancer of the
cervix, while variable, is usually measured in years. Regular screen
ing of the cervix should identify a pre-malignant ccr cal lesion.
s hich ma be effectively and simply treated by a specialist in the
area. Of note, half of the women with cervical cancer has c never had
a Pap smear, and one quarter of the cases (11 of the deaths occur
in women h5 years of ace orolder. Ii is important to note that ss omen
v ho are postinenopausal still require Pap smear scrceniitg earls
\esver methods of screening arc currentl being investigated. One
approach is the detection of a high—risk vaginal HPV infection as a
prediction of likelihood to develop cervical cancer. C’ui-rentl . HPV
screening is only useful in the context of a mildl abnormal ( ASC—
[S Pap smear.
Despite the limitations of a Pap smear, three yearly Pap smears
ss ill lower the risk of dying fmm cervical cancer h\ over ShY
Abnormal Pap smears result in colposcopic evaluation and directed
cervical hiops In some cases. pre—malignant disease can be fol—
losved over time. Other more extensis e pre-malignant disease is
treated ss ith crotherapx. laser apori/ation. cervical conization.
h sterectomy or more commonly. LEEP.
For women diagnosed with invasive cancer. the signs and s mp
toms ma\ be silent until there is advanced disease. Some ss omen
ma report postcoital bleeding. a foul vaginal discharge. or othei
abnormal bleeding. Signs of advanced cancer may he pelvic pain.
unilateral leg edema or pain. A pel\ ic mass or grossl\ visible
cervical lesion may also be noted.
Patients diagnosed with invasive cervical cancer should he re
lerred to a gynecologic oncologist. Very early disease in selected
patients who desire preservation of fertility can he treated conserva
tively with a cervical conization or radical trachelectomy. Surgical
care of advanced local disease is accomplished with radical hyster
ectomy and pelvic lymphadenectomy.
For those cancers that are too large for radical hysterectomy or
ones that have spread beyond the cervix, chemoradiation therapy is
the treatment of choice. Recent studies have shown that a combina
tion of radiation plus cisplatin offers the best hope for women with
advanced cervical cancer, External beam radiation targets both the
primary tumor and the other pelvic tissues, including the pelvic
lymph nodes. This is followed by two or more radiation cervical
implants. also known as brachytherapy. It has been recently demon
strated that the use of concurrent cisplatin—based chemotherapy ss ith
radiation significantly improves the chances of survival b acting as
a radiation sensitizer and also decreasing the chance of distant
spread.
Pie—malignant cervical disease. dvsplasia. has a nearl\ I (hI’ five—
ear sin’S is al. Early invasive disease is highl curable ss ith radical
surger or radiotherapy and fis e- car surs m val rates are nearly Sh(
Lnfortunatel . distato disease is irtuall incurable. Clinical trials
utilizing ness lv developed drugs are currentl as ai lable in Haw ai I
In addition. there arc now HPV therapeutic vaccinations designed to
sti n ni ate ihe i inniune system against metastat ic disease in earl
trials.
The management of recurrent cervical cancer is problematic. For
those women who have not received primar radiation as initial
therapy, chemoradiation may be curative or palliative. An occa
sional isolated soft-tissue recurrence may he treated 1w resection
with long-term survival. The use of chenlotherap\ is palliative in
nature and has relatively little impact on the length aitd qualit of
life.
Vulvar and vaginal cancer, although uncommon. are easily treat
able if caught early. Both are similarly thought to be caused 1w the
HPV sims.
Promising research is now under sva\ in the field of cervical
cancer prevention. The most exciting work ins olves the de\ elop—
nlent of a vaccine acainst the hunian papil loma s imus. Vaccines are
being designed (‘or both proph\ lax is and therap At the Unis ersit\
of Hawaii. we have opened a new HPV s accine trial for the
prophvlaxis of HPV infections. To be enrolled, women oust not
have heeti infected with the HPV virus. If this trial is successful at
preventing HPV infection, it will have tile most significant inipaci
in histor on cancer prevetition. Of critical nnportance is to encour
age participation ol women with cers ical cancer and other malig—
nancies in clinical trials. Adult participation ni clinical trials is
currentl less than 5ft across the nation. If we are to make an
progress against this disease. development of iess treatments, and
hence, clinical trial participation is absolutely essential.
Endometrial Cancer
Endometrial cancer is the most common pelvic malignancy iii the
United States affecting rtearl 10.()00 women a year. Six thousand
five—hundred women died of endometrial cancer in the ear 2000.
representing a dramatic 224 increase in the past decade.
It is hypothesized that there are two natural history courses for
endoinetrial cancer: Type I, which is estrogeil related, and Type 2,
which is unrelated to estrogen stimulation and much more common
in the United States. Type I is seen in younger. heax icr patients.
tends t he lower grade, and involves exogenous estrogen. Type 2
occurs itl older and thinner women as well as those endometrial
cancers that have a genetic basis, especially hereditary non-polypo
sis colon cancer (HNPCC).
Several constitutional factors have been identified in women who
develop endometrial cancer including obesity, nulliparity. late meno
pause, unopposed estrogen, diabetes, and hypertension. Obesity is
the greatest risk factor. Atypical endometrial hvperplasia is the pre
malignant precursor of Type I eridometrial cancer. Virtually all of
these patients, if left untreated, will develop ins asive endornetrial
cancer over time. Fortunately, a simple h sterectoni\ svill eliminate
the chance of metastatic disease, Women with a histor of breast
cancer who take Tamoxifen have a slightly increased risk of en—
dometrial cancer and uterine sarcoma . Abnormal bleeding while on
this medication always prompts immediate ins cstigation with en—
dometrial sampling. Interestingl\ . Raloxitene does not increase the
risk of endometrial cancer.
Os er SHY of all ss omen with endometrial cancer present ss ith
postnteriopaucal bleeding. There are no satis(actor\ si a s to screen
or endomnetria l canceL Pap smears do not screen (or endometrial
cancer. However. Pap smeam’s mes calm ng atypical clandular cells or
malignant endonietrial cells frequently lead to the diagnosis of
end metrmal cancer. Wonien is itli post oem pa Li sal i r ahnornia I
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perimenopausal bleeding should be evaluated with endometrial
biopsy. High—risk women over 35 with menomettrhagia should also
he hiopsied. Ultrasound can he useful in the evaluation of abnormal
hleedin. If the endometrial stripe is less than 5mm, the risk of
endometrial cancer is virtually elevated. Recun’ent bleeding is an
indication thr endometrial sampling es en fan ultrasound is normal.
The stirs ival of patients ss ith endometrial cancer is correlaied with
the stage ol disease. Endometrial cancer is highly curable if caught
early. Stage I disease is cured in os er 9t of cases while distant
disease realizes only a IOU long—term cure rate.
Surgery is the cornerstone ofendometrial cancer theraps. Once a
diagnosis ol endometrial cancer is made. the patient should be
reterred to a g necolocic oncologist. Vi ith the exception of ‘.erv
small. carE . icin—invasis e. grade I lesions, all patients should
undergo a staging procedure including hsterectorn
salpingooopherectomv, and pels ic and para—aortic lymphadenec—
tom\ If more extensive disease is found, radical resection is
indicated.
Recent studies have confirmed the benefit of complete lym
phadenectomy in endometrial cancer patients. In the year 2000, a
University of Alabama study found an improvement in survival in
even early staged patients undergoing complete lymphadenectomy.
This is presumably due to the resection of clinically occult micro
scopic melastatic foci.
Recent publications have called into question the role of radiation
therap for patients with locally ads anced endometrial cancer. A
large Gs necologic Oncology Group trial (GOC 99) found no statis
tical improvement in survival for patients with hLgh—nsk earl and
localE advanced disease treated with adjuvant radiation therap\
although pelvic disease ssas controlled.
Advanced and recurrent endometrial cancer can be treated using
several therapies. sometimes quite successfully A current GOG
trial open in Hawaii offers radiation theraps. chemotherapy with
plati n tim. Taxol. and Adriamvcin. as ss eli as hormonal therap ss ith
Tamo\ifen and Megace.
I.osser grade endometrial cancers are estrogen receptor positise
and frequently have dramatic responses even with widely metastatic
disease to hormonal therapy. Becausc of the estrogen receptors seen
in endoinetrial cancer, hormone replacement therapy has tradition-
all) been withheld. Retrospective studies, however, have found no
detriment to survival with HRT. The GOG has an ongoing prospec
tive randomized-blinded trial to answer definitively this very ques
tion. Paiients in Hawaii diagnosed with endometrial cancer can
choose to he a part of this study.
The future includes tumor biology. Ci necologic researchers have
turned to molecular biology in an attempt to elucidate the etiology
of these cancers. Recentresearch describing I)NA ploidy. oncogene.
and tumor suppressor gene mutations common to these malignan
cies is providnig a basis (or molecular genesis of there cancers. For
example. l)>A ploid is an independent quantifiable predictor of
progression_free surs ival in palienis ss ith endometrial cancer. Aneu—
ploid implies the presence ol an ahnormal quantity of venomic
material and imparts a less favorable prognosis. The overexpression
of scs eral iegtilatory genes. such as c-tms. K-ias. HE R-2ineu. and
p3. also niav harbor prognostic signi icance in endometrial cancer.
\lolccnlar evenc may dererminc s anon’ hehas moral characteristics
ot tumors. Therefore, the identilicaimon ol molecular sariahles ma
assist clinicians in determining patient risk status and in selecting
treatment options.
Beyond molectilar research. reducing obesity in the United States
would be an immediate way to reverse the increasing incidence of
endometrial cancer. Additionall\ . the use of oral contraceptives in
high—risk patients tinder Sf) ss ould dramatically lower the risk ot
endometrial cancer. FinalE . persuading patients to seek medical
attention for abnormal bleeding and encouraging ph sicians in
perform evaluations with anx signs ol bleeding would go a long ss a)
toss ard maximizing survival.
Conclusion
a physician and scientist, there is no better time in hisior in he
ins oh ed in the understanding and advancement to treatment for
g necologic cancers. So much is being discos ered es er da . Theme
are exciting new serun markers for the detection of early os ariail
cancer. prophylactic vaccinations that could eliminate cervical
cancer all together. and ads ances in the surgical treatment ot
endometrial cancer. Part of our mission is to allow our patients the
opportunity to participate in potentially life—saving treatment and
screening trials, many of which are available right here at home in
Hawaii.
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